Sun Pharma shares surge over 5% following landmark Organon acquisition. Indian pharmaceutical giant Sun Pharmaceutical announced an all-cash deal to acquire US-based Organon & Co for $11.75 billion, the largest overseas acquisition by an Indian drugmaker. The stock jumped to an intraday high of ₹1,709 on the NSE, up from the previous close of ₹1,620.40, reflecting strong investor confidence. Under the agreement, Sun Pharma will acquire all outstanding shares at $14 per share. This strategic expansion significantly strengthens the company's global footprint and positions it more competitively in key US therapeutic segments. Market analysts view this acquisition as a pivotal growth driver, though execution and integration success will be critical to realizing long-term value creation and earnings impact.
